BET-inhibitor DYB-41 reduces pulmonary inflammation and local and systemic cytokine levels in LPS-induced acute respiratory distress syndrome: an experimental rodent study.

Iten, Manuela; Gschwend, Camille; Ostini, Alessandro; Cameron, David Robert; Goepfert, Christine; Berger, David; Haenggi, Matthias (2024). BET-inhibitor DYB-41 reduces pulmonary inflammation and local and systemic cytokine levels in LPS-induced acute respiratory distress syndrome: an experimental rodent study. Intensive care medicine experimental, 12(19) Springer 10.1186/s40635-024-00604-z

[img]
Preview
Text
s40635-024-00604-z.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (1MB) | Preview

BACKGROUND

Acute respiratory distress syndrome (ARDS) is a form of respiratory failure stemming from various underlying conditions that ultimately lead to inflammation and lung fibrosis. Bromodomain and Extra-Terminal motif (BET) inhibitors are a class of medications that selectively bind to the bromodomains of BET motif proteins, effectively reducing inflammation. However, the use of BET inhibitors in ARDS treatment has not been previously investigated. In our study, we induced ARDS in rats using endotoxin and administered a BET inhibitor. We evaluated the outcomes by examining inflammation markers and lung histopathology.

RESULTS

Nine animals received treatment, while 12 served as controls. In the lung tissue of treated animals, we observed a significant reduction in TNFα levels (549 [149-977] pg/mg vs. 3010 [396-5529] pg/mg; p = 0.009) and IL-1β levels (447 [369-580] pg/mg vs. 662 [523-924] pg/mg; p = 0.012), although IL-6 and IL-10 levels showed no significant differences. In the blood, treated animals exhibited a reduced TNFα level (25 [25-424] pg/ml vs. 900 [285-1744] pg/ml, p = 0.016), but IL-1β levels were significantly higher (1254 [435-2474] pg/ml vs. 384 [213-907] pg/ml, p = 0.049). No differences were observed in IL-6 and IL-10 levels. There were no significant variations in lung tissue levels of TGF-β, SP-D, or RAGE. Histopathological analysis revealed substantial damage, with notably less perivascular edema (3 vs 2; p = 0.0046) and visually more inflammatory cells. However, two semi-quantitative histopathologic scoring systems did not indicate significant differences.

CONCLUSIONS

These preliminary findings suggest a potential beneficial effect of BET inhibitors in the treatment of acute lung injury and ARDS. Further validation and replication of these results with a larger cohort of animals, in diverse models, and using different BET inhibitors are needed to explore their clinical implications.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Intensive Care, Emergency Medicine and Anaesthesiology (DINA) > Clinic of Intensive Care
05 Veterinary Medicine > Department of Infectious Diseases and Pathobiology (DIP) > Institute of Animal Pathology
05 Veterinary Medicine > Department of Infectious Diseases and Pathobiology (DIP)

UniBE Contributor:

Iten, Manuela, Ostini, Alessandro, Cameron, David Robert, Göpfert, Christine, Berger, David, Hänggi, Matthias

Subjects:

600 Technology > 630 Agriculture
600 Technology > 610 Medicine & health

ISSN:

2197-425X

Publisher:

Springer

Language:

English

Submitter:

Pubmed Import

Date Deposited:

28 Feb 2024 12:32

Last Modified:

28 Feb 2024 12:42

Publisher DOI:

10.1186/s40635-024-00604-z

PubMed ID:

38407669

Uncontrolled Keywords:

ARDS Acute lung injury BET-inhibitor Lung fibrosis

BORIS DOI:

10.48350/193440

URI:

https://boris.unibe.ch/id/eprint/193440

Actions (login required)

Edit item Edit item
Provide Feedback